Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Acute Mixed-Phenotype Leukemia|Cancer|Refractory|Progression|Diffuse Large B Cell Lymphoma|Multiple Myeloma|Lymphoma|Lymphoma, Non-Hodgkin|Myeloma, Plasma-Cell|Myelomatosis|Plasma Cell Myeloma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
DRUG: BMF-219
Determine Optimal Biologic Dose (OBD) and RP2D of BMF-219 monotherapy for (Cohorts 1, 2, 3 & 4), Determine Optimal Biologic Dose (OBD) and recommended Phase 2 dose (RP2D) of BMF-219 monotherapy in subjects with refractory or relapsed (R/ R) acute leukemia (Cohort 1), diffuse large B-cell lymphoma (Cohort 2), multiple myeloma (Cohort 3), and chronic lymphocytic leukemia/ small lymphocytic lymphoma (Cohort 4)., At the end of Cycle 1 (each Cycle is 28 Days in duration)
Evaluate the Safety treatment-emergent TEAEs and SAEs, Evaluate the Safety of BMF-219 as expressed by treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)., At the end of Cycle 1 (each Cycle is 28 Days in duration)
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) with mixed lineage leukemia 1-rearranged (KMT2A/ MLL1r), nucleophosmin 1 (NPM1), diffuse large b-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic lymphoma (CLL)/ small lymphocytic lymphoma (SLL).